SANUWAVE Health Submits Final Module of PMA Application for FDA Approval of dermaPACE

Comments
Loading...
SANUWAVE Health, Inc. SNWV today announced that it has submitted to the U.S. Food and Drug Administration the third and final module of its Premarket Approval application for the dermaPACE device for the treatment of diabetic foot ulcers.
SNWV Logo
SNWVSANUWAVE Health Inc
$37.0024.2%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum99.32
Growth79.24
Quality-
Value20.96
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: